Detection of FGFR2 : FAM76A Fusion Gene in Circulating Tumor RNA Based on Catalytic Signal Amplification of Graphene Oxide‐loaded Magnetic Nanoparticles. Issue 10 (4th July 2018)

• Record Type: Journal Article
• Authors: Gorgannezhad, Lena; Umer, Muhammad; Kamal Masud, Mostafa; Hossain, Md. Shahriar A.; Tanaka, S.; Yamauchi, Y.; Salomon, Carlos; Kline, Richard; Nguyen, Nam‐Trung; Shiddiky, Muhammad J. A.
• Is Part Of: Electroanalysis. Volume 30:Issue 10(2018)
• Page Start: 2293
• Page End: 2301
• Publication Date: 2018-07-04
• Subjects: Biosensors -- Cancer -- Fusion Genes -- GO Coated Magnetic Nanoparticles -- Liquid Biopsy; Electrochemical analysis -- Periodicals; Chemistry, Analytical -- Periodicals; Electrochemistry -- Periodicals; 543.4
• DOI: 10.1002/elan.201800282
• Languages: English
• ISSNs: 1040-0397

Abstract

Abstract: Circulating tumor nucleic acids (ctNAs) are promising biomarkers for minimally invasive cancer assessment. The FGFR2 : FAM76A fusion gene is one of the highly promising ovarian cancer biomarkers detectable in ctNAs. Herein, we introduce a new amplification‐free electrochemical assay for the detection of FGFR2 : FAM76A fusion gene in ctNAs extracted from ovarian cancer patients. The assay relies on the electrocatalytic activity of a new class of superparamagnetic graphene‐loaded iron oxide nanoparticles (GO‐NPFe2 O3 ). After isolation and purification, the target RNA was directly adsorbed onto the GO‐NPFe2 O3 surface through graphene‐RNA affinity interaction. The electrocatalytic signal was achieved by the reduction of surface‐attached ruthenium hexaammine(III) chloride which was further amplified by using the ferricyanide redox system. Our assay depicted an excellent detection sensitivity down to 1.0 fM, high specificity and excellent reproducibility (% RSD=<5 %, for n=3). The analytical performance of our method was validated with standard qRT‐PCR analysis. We believe that this newly developed assay would be practically applicable in clinical research. Abstract :